TORONTO, ONTARIO--(Marketwired - July 23, 2014) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive Licensing and Distribution Agreement with an existing European partner for a new product that will be marketed by its' Hospital Products Division. The new product utilizes a patented delivery system that offers technical advantages over existing alternatives and will be used in hospitals and acute care settings. These products will provide hospitals, clinics, and healthcare professionals with improved patient safety as well as operational efficiencies. The product will be launched after Health Canada approval.

"This is the third product that we have in-licensed from the same partner that uses the same underlying patented technology. The first of the three is already approved and being prepared for launch later this year or early next, and the second is in the latter stages of the Health Canada approval process," said René Goehrum, President and CEO of BioSyent. "We have already started discussions and due diligence with our European partner on the fourth product that utilizes this technology and we are aware that they are developing more such products. This new product deal brings the combined number of products that BioSyent Pharma has either in-market, Health Canada approved, or in-licensed to eight."

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.

Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

At the date of this press release the Company had 13,801,195 shares issued and outstanding.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.

Contact Information:

BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013